| Glioblastoma is a fast-growing and aggressive brain tumor. |
| 1336- | 2DG, | 2-deoxy-D-glucose induces oxidative stress and cell killing in human neuroblastoma cells |
| - | in-vitro, | GBM, | SK-N-SH |
| 3452- | 5-ALA, | 5-ALA Is a Potent Lactate Dehydrogenase Inhibitor but Not a Substrate: Implications for Cell Glycolysis and New Avenues in 5-ALA-Mediated Anticancer Action |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | LN-18 | - | in-vitro, | GBM, | U87MG |
| 1094- | ACNs, | Anthocyanidins inhibit epithelial-mesenchymal transition through a TGF-β/Smad2 signaling pathway in glioblastoma cells: Anthocyanidins inhibit TGF-β-mediated EMT. |
| - | in-vitro, | GBM, | U87MG |
| 235- | AL, | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
| - | in-vitro, | GBM, | U87MG |
| 248- | AL, | Allicin inhibits cell growth and induces apoptosis in U87MG human glioblastoma cells through an ERK-dependent pathway |
| - | in-vitro, | GBM, | U87MG |
| 2663- | AL, | Therapeutic Effect of Allicin on Glioblastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 1157- | And, | Andrographolide suppresses the migratory ability of human glioblastoma multiforme cells by targeting ERK1/2-mediated matrix metalloproteinase-2 expression |
| - | in-vitro, | GBM, | GBM8401 | - | in-vitro, | GBM, | U251 |
| 307- | Api, | Flavonoids inhibit angiogenic cytokine production by human glioma cells |
| - | in-vitro, | GBM, | GL-15 |
| 308- | Api, | Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U373MG |
| 2319- | Api, | Apigenin sensitizes radiotherapy of mouse subcutaneous glioma through attenuations of cell stemness and DNA damage repair by inhibiting NF-κB/HIF-1α-mediated glycolysis |
| - | in-vitro, | GBM, | NA |
| 3345- | ART/DHA, | Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells |
| - | in-vitro, | GBM, | NA |
| 575- | ART/DHA, | Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition |
| - | in-vitro, | GBM, | U87MG |
| 571- | ART/DHA, | TMZ, | Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence |
| - | vitro+vivo, | GBM, | A172 | - | vitro+vivo, | GBM, | U87MG |
| 569- | ART/DHA, | Dihydroartemisinin exhibits anti-glioma stem cell activity through inhibiting p-AKT and activating caspase-3 |
| - | in-vitro, | GBM, | NA |
| 1357- | Ash, | Cytotoxicity of withaferin A in glioblastomas involves induction of an oxidative stress-mediated heat shock response while altering Akt/mTOR and MAPK signaling pathways |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | GL26 |
| 4817- | ASTX, | Low Dose Astaxanthin Treatments Trigger the Hormesis of Human Astroglioma Cells by Up-Regulating the Cyclin-Dependent Kinase and Down-Regulated the Tumor Suppressor Protein P53 |
| - | in-vitro, | GBM, | U251 |
| 2619- | Ba, | Tumor cell membrane-coated continuous electrochemical sensor for GLUT1 inhibitor screening |
| - | in-vitro, | HCC, | HepG2 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | BC, | MGC803 | - | in-vitro, | Lung, | A549 |
| 1401- | BBR, | Berberine induces apoptosis in glioblastoma multiforme U87MG cells via oxidative stress and independent of AMPK activity |
| - | in-vitro, | GBM, | U87MG |
| 1402- | BBR, | Berberine-induced apoptosis in human glioblastoma T98G cells is mediated by endoplasmic reticulum stress accompanying reactive oxygen species and mitochondrial dysfunction |
| - | in-vitro, | GBM, | T98G |
| 2700- | BBR, | Cell-specific pattern of berberine pleiotropic effects on different human cell lines |
| - | in-vitro, | GBM, | U343 | - | in-vitro, | GBM, | MIA PaCa-2 | - | in-vitro, | Nor, | HDFa |
| 2693- | BBR, | Antitumor Effects of Berberine on Gliomas via Inactivation of Caspase-1-Mediated IL-1β and IL-18 Release |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 2757- | BetA, | Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways |
| - | in-vitro, | GBM, | U251 |
| 2731- | BetA, | Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives |
| - | Review, | GBM, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 729- | Bor, | Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | Nor, | HaCaT |
| 738- | Bor, | Borax induces ferroptosis of glioblastoma by targeting HSPA5/NRF2/GPx4/GSH pathways |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Nor, | SVGp12 |
| 739- | Bor, | Borax regulates iron chaperone- and autophagy-mediated ferroptosis pathway in glioblastoma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | HMC3 |
| 745- | Bor, | Investigation of cytotoxic antiproliferative and antiapoptotic effects of nanosized boron phosphate filled sodium alginate composite on glioblastoma cancer cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | Nor, | L929 | - | in-vitro, | GBM, | T98G |
| 4489- | Chit, | Se, | Inhibiting Metastasis and Improving Chemosensitivity via Chitosan-Coated Selenium Nanoparticles for Brain Cancer Therapy |
| - | in-vitro, | GBM, | U87MG |
| 2590- | CHr, | Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the ERK/Nrf2 signaling pathway |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG |
| 952- | Cin, | Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | GBM, | U251 | - | in-vivo, | Ovarian, | SKOV3 |
| 480- | CUR, | Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells |
| - | in-vitro, | GBM, | SNB19 |
| - | Analysis, | GBM, | NA |
| 1873- | DCA, | Dual-targeting of aberrant glucose metabolism in glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1851- | dietFMD, | Chemo, | Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | neuroblastoma, | SH-SY5Y |
| 2273- | dietMet, | Methionine and cystine double deprivation stress suppresses glioma proliferation via inducing ROS/autophagy |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 4917- | DSF, | Chemo, | Cu, | Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma |
| - | Trial, | GBM, | NA |
| 657- | EGCG, | MNPs, | MF, | Interaction of poly-l-lysine coating and heparan sulfate proteoglycan on magnetic nanoparticle uptake by tumor cells |
| - | in-vitro, | GBM, | U87MG |
| 658- | EGCG, | MNPs, | MF, | Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface |
| - | in-vitro, | GBM, | LN229 |
| - | in-vitro, | GBM, | U87MG |
| 2497- | Fenb, | In vitro anti-tubulin effects of mebendazole and fenbendazole on canine glioma cells |
| - | in-vitro, | GBM, | NA |
| 1914- | Fer, | VitC, | TMZ, | Rad, | Pharmacologic Ascorbate and Ferumoxytol Combined with Temozolomide and Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma |
| - | Trial, | GBM, | NA |
| 987- | GA, | Targeting Aerobic Glycolysis: Gallic Acid as Promising Anticancer Drug |
| - | in-vitro, | GBM, | AMGM | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | BC, | MCF-7 |
| 1967- | GamB, | Gambogic acid induces apoptotic cell death in T98G glioma cells |
| - | in-vitro, | GBM, | T98G |
| 819- | GAR, | Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in STAT3/5A-Addicted Glioblastoma |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | GBM, | GBM |
| 2511- | H2, | Molecular hydrogen suppresses glioblastoma growth via inducing the glioma stem-like cell differentiation |
| - | in-vivo, | GBM, | U87MG |
| 1412- | HCA, | Identification of ATP Citrate Lyase as a Positive Regulator of Glycolytic Function in Glioblastomas |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 1438- | HCQ, | Chemo, | Adding Chloroquine to Conventional Treatment for Glioblastoma Multiforme |
| - | Trial, | GBM, | NA |
| 1441- | HCQ, | Chemo, | Case report: stage 4 pancreatic cancer to remission using paricalcitol and hydroxychloroquine in addition to traditional chemotherapy |
| - | Case Report, | GBM, | NA |
| 1912- | HCQ, | TMZ, | Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy |
| - | in-vivo, | GBM, | U87MG |
| 1153- | HNK, | Honokiol Eliminates Glioma/Glioblastoma Stem Cell-Like Cells via JAK-STAT3 Signaling and Inhibits Tumor Progression by Targeting Epidermal Growth Factor Receptor |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 2082- | HNK, | Revealing the role of honokiol in human glioma cells by RNA-seq analysis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1070- | IVM, | Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation |
| - | vitro+vivo, | GBM, | NA |
| 1919- | JG, | The Anti-Glioma Effect of Juglone Derivatives through ROS Generation |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 |
| 1922- | JG, | Juglone induces apoptosis of tumor stem-like cells through ROS-p38 pathway in glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 2903- | LT, | Luteolin induces apoptosis by ROS/ER stress and mitochondrial dysfunction in gliomablastoma |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vivo, | NA, | NA |
| 4778- | Lyco, | Lycopene exerts cytotoxic effects by mitochondrial reactive oxygen species–induced apoptosis in glioblastoma multiforme |
| - | in-vitro, | GBM, | GBM8401 |
| 2545- | M-Blu, | Reversing the Warburg Effect as a Treatment for Glioblastoma |
| - | in-vitro, | GBM, | U87MG | - | NA, | AD, | NA | - | in-vitro, | GBM, | A172 | - | in-vitro, | GBM, | T98G |
| 2500- | meben, | Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA |
| 995- | MEL, | Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma |
| - | vitro+vivo, | GBM, | NA |
| 2260- | MF, | Alternative magnetic field exposure suppresses tumor growth via metabolic reprogramming |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 | - | in-vivo, | NA, | NA |
| 3485- | MF, | Cytoprotective effects of low-frequency pulsed electromagnetic field against oxidative stress in glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 3458- | MF, | Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy |
| - | in-vitro, | GBM, | NA |
| 535- | MF, | Electromagnetic Fields Trigger Cell Death in Glioblastoma Cells through Increasing miR-126-5p and Intracellular Ca2+ Levels |
| - | in-vitro, | Pca, | PC3 | - | in-vitro, | GBM, | A172 | - | in-vitro, | Pca, | HeLa |
| 528- | MF, | Caff, | Pulsed electromagnetic fields affect the intracellular calcium concentrations in human astrocytoma cells |
| - | in-vitro, | GBM, | U373MG |
| 536- | MF, | Comparison of pulsed and continuous electromagnetic field generated by WPT system on human dermal and neural cells |
| - | in-vitro, | Nor, | SH-SY5Y | - | in-vitro, | GBM, | T98G | - | in-vitro, | Nor, | HDFa |
| 529- | MF, | Low-frequency magnetic field therapy for glioblastoma: Current advances, mechanisms, challenges and future perspectives |
| - | Review, | GBM, | NA |
| 188- | MFrot, | MF, | Spinning magnetic field patterns that cause oncolysis by oxidative stress in glioma cells |
| - | in-vitro, | GBM, | GBM115 | - | in-vitro, | GBM, | DIPG |
| 187- | MFrot, | MF, | Method for noninvasive whole-body stimulation with spinning oscillating magnetic fields and its safety in mice |
| - | in-vivo, | GBM, | NA |
| 203- | MFrot, | MF, | Rotating Magnetic Field Induced Oscillation of Magnetic Particles for in vivo Mechanical Destruction of Malignant Glioma |
| - | vitro+vivo, | GBM, | U87MG |
| 185- | MFrot, | MF, | Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device |
| - | Human, | GBM, | NA |
| 216- | MFrot, | MF, | Elongated Nanoparticle Aggregates in Cancer Cells for Mechanical Destruction with Low Frequency Rotating Magnetic Field |
| - | in-vitro, | GBM, | U87MG |
| 184- | MFrot, | MF, | Rotating Magnetic Fields Inhibit Mitochondrial Respiration, Promote Oxidative Stress and Produce Loss of Mitochondrial Integrity in Cancer Cells |
| - | in-vitro, | GBM, | GBM |
| 186- | MFrot, | MF, | Selective induction of rapid cytotoxic effect in glioblastoma cells by oscillating magnetic fields |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Lung, | NA |
| 516- | MFrot, | immuno, | MF, | Anti-tumor effect of innovative tumor treatment device OM-100 through enhancing anti-PD-1 immunotherapy in glioblastoma growth |
| - | vitro+vivo, | GBM, | U87MG |
| 3493- | MFrot, | MF, | Mechanical nanosurgery of chemoresistant glioblastoma using magnetically controlled carbon nanotubes |
| - | in-vivo, | GBM, | NA |
| 2258- | MFrot, | MF, | EXTH-68. ONCOMAGNETIC TREATMENT SELECTIVELY KILLS GLIOMA CANCER CELLS BY INDUCING OXIDATIVE STRESS AND DNA DAMAGE |
| - | in-vitro, | GBM, | GBM | - | in-vitro, | Nor, | SVGp12 |
| 2259- | MFrot, | MF, | Method and apparatus for oncomagnetic treatment |
| - | in-vitro, | GBM, | NA |
| 4569- | MFrot, | Case Report: A new noninvasive device-based treatment of a mesencephalic H3 K27M glioma |
| - | Case Report, | GBM, | NA |
| 1911- | Nos, | Noscapine inhibits tumor growth in TMZ-resistant gliomas |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 959- | PACs, | Grape seed extract inhibits VEGF expression via reducing HIF-1α protein expression |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | BC, | MDA-MB-231 |
| 2037- | PB, | Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria |
| - | in-vitro, | GBM, | NA | - | in-vivo, | GBM, | NA |
| 2045- | PB, | Phenylbutyrate—a pan-HDAC inhibitor—suppresses proliferation of glioblastoma LN-229 cell line |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | LN-18 |
| 2063- | PB, | Rad, | Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation |
| - | in-vitro, | GBM, | U87MG | - | NA, | NA, | U251 |
| 2066- | PB, | Rad, | Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas |
| - | in-vitro, | GBM, | U251 |
| 2065- | PB, | TMZ, | Inhibition of Mitochondria- and Endoplasmic Reticulum Stress-Mediated Autophagy Augments Temozolomide-Induced Apoptosis in Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 2025- | PB, | Complete response of a recurrent, multicentric malignant glioma in a patient treated with phenylbutyrate |
| - | Case Report, | GBM, | NA |
| 2026- | PB, | Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: A dose escalation and pharmacologic study |
| - | Trial, | GBM, | NA |
| 1940- | PL, | Piperlongumine Inhibits Migration of Glioblastoma Cells via Activation of ROS-Dependent p38 and JNK Signaling Pathways |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 1943- | PL, | Piperlongumine treatment inactivates peroxiredoxin 4, exacerbates endoplasmic reticulum stress, and preferentially kills high-grade glioma cells |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 1948- | PL, | born, | Natural borneol serves as an adjuvant agent to promote the cellular uptake of piperlongumine for improving its antiglioma efficacy |
| - | in-vitro, | GBM, | NA |
| 2951- | PL, | Aur, | Synergistic Dual Targeting of Thioredoxin and Glutathione Systems Irrespective of p53 in Glioblastoma Stem Cells |
| - | in-vitro, | GBM, | U87MG |
| 2949- | PL, | Piperlongumine selectively kills glioblastoma multiforme cells via reactive oxygen species accumulation dependent JNK and p38 activation |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 3371- | QC, | Quercetin induces MGMT+ glioblastoma cells apoptosis via dual inhibition of Wnt3a/β-Catenin and Akt/NF-κB signaling pathways |
| - | in-vitro, | GBM, | T98G |
| 3339- | QC, | Quercetin suppresses ROS production and migration by specifically targeting Rac1 activation in gliomas |
| - | in-vitro, | GBM, | C6 | - | in-vitro, | GBM, | IMR32 |
| 3072- | RES, | Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2/STAT3 pathway |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | U87MG |
| 2989- | RES, | Resveratrol Represses Pokemon Expression in Human Glioma Cells |
| - | in-vitro, | GBM, | NA |
| 3006- | RosA, | Rosmarinic acid attenuates glioblastoma cells and spheroids’ growth and EMT/stem-like state by PTEN/PI3K/AKT downregulation and ERK-induced apoptosis |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | LN229 |
| 3011- | RosA, | Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition |
| - | in-vitro, | GBM, | SH-SY5Y | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | HEK293 | - | in-vitro, | Nor, | MCF10 |
| 4713- | Se, | VitC, | VitK3, | Selenium supplementation protects cancer cells from the oxidative stress and cytotoxicity induced by the combination of ascorbate and menadione sodium bisulfite |
| - | in-vitro, | GBM, | NA |
| 4501- | Se, | Mechanisms of the Cytotoxic Effect of Selenium Nanoparticles in Different Human Cancer Cell Lines |
| - | in-vitro, | GBM, | A172 | - | in-vitro, | Colon, | Caco-2 | - | in-vitro, | Pca, | DU145 | - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Nor, | L929 |
| 1062- | Sel, | Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells |
| - | in-vitro, | GBM, | LN229 | - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 3183- | SFN, | Sulforaphane potentiates the efficacy of chemoradiotherapy in glioblastoma by selectively targeting thioredoxin reductase 1 |
| - | in-vitro, | GBM, | NA |
| 1735- | SFN, | Activation of multiple molecular mechanisms for apoptosis in human malignant glioblastoma T98G and U87MG cells treated with sulforaphane |
| - | in-vitro, | GBM, | T98G | - | in-vitro, | GBM, | U87MG |
| 1464- | SFN, | d,l-Sulforaphane Induces ROS-Dependent Apoptosis in Human Gliomablastoma Cells by Inactivating STAT3 Signaling Pathway |
| - | in-vitro, | GBM, | NA |
| 3302- | SIL, | Protective effects of silymarin in glioblastoma cancer cells through redox system regulation |
| - | in-vitro, | GBM, | U87MG |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2362- | SK, | RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide |
| - | in-vitro, | GBM, | U87MG | - | in-vivo, | GBM, | NA | - | in-vitro, | GBM, | U251 |
| 1346- | SK, | An Oxidative Stress Mechanism of Shikonin in Human Glioma Cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 |
| 1344- | SK, | Novel multiple apoptotic mechanism of shikonin in human glioma cells |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | Hs683 | - | in-vitro, | GBM, | M059K |
| 1342- | SK, | RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species |
| - | in-vitro, | GBM, | NA | - | in-vivo, | NA, | NA |
| 333- | SNP, | HPT, | Enhancement effect of cytotoxicity response of silver nanoparticles combined with thermotherapy on C6 rat glioma cells |
| - | in-vivo, | GBM, | NA |
| 328- | SNP, | Rad, | Silver nanoparticles outperform gold nanoparticles in radiosensitizing U251 cells in vitro and in an intracranial mouse model of glioma |
| - | vitro+vivo, | GBM, | U251 |
| 329- | SNP, | Rad, | Enhancement of radiotherapy efficacy by silver nanoparticles in hypoxic glioma cells |
| - | in-vitro, | GBM, | U251 |
| 330- | SNP, | Rad, | Reactive oxygen species acts as executor in radiation enhancement and autophagy inducing by AgNPs |
| - | in-vitro, | GBM, | U251 |
| 331- | SNP, | Rad, | Silver nanoparticles: a novel radiation sensitizer for glioma? |
| - | vitro+vivo, | GBM, | NA |
| 332- | SNP, | Rad, | Enhancement of Radiosensitization by Silver Nanoparticles Functionalized with Polyethylene Glycol and Aptamer As1411 for Glioma Irradiation Therapy |
| - | in-vivo, | GBM, | NA |
| 4563- | SNP, | Rad, | Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study |
| - | in-vitro, | BC, | MCF-7 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | Melanoma, | A431 |
| 4403- | SNP, | Silver Nanoparticles Decorated UiO-66-NH2 Metal-Organic Framework for Combination Therapy in Cancer Treatment |
| - | in-vitro, | GBM, | U251 | - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | GL26 | - | in-vitro, | Cerv, | HeLa | - | in-vitro, | CRC, | RKO |
| 4399- | SNP, | Chit, | Silver nanoparticles impregnated alginate-chitosan-blended nanocarrier induces apoptosis in human glioblastoma cells |
| - | in-vitro, | GBM, | U87MG |
| 4358- | SNP, | HPT, | Rad, | Silver nanocrystals mediated combination therapy of radiation with magnetic hyperthermia on glioma cells |
| - | in-vitro, | GBM, | U251 |
| 2127- | TQ, | Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways |
| - | Review, | GBM, | NA |
| 2413- | TTT, | Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression |
| - | in-vitro, | GBM, | U87MG |
| 2412- | TTT, | A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights |
| - | Review, | GBM, | NA |
| 3747- | TTT, | Tumor treating induced fields: a new treatment option for patients with glioblastoma |
| - | in-vitro, | GBM, | U87MG |
| 1218- | VitC, | ASA, | Ascorbic acid enhances the inhibitory effect of aspirin on neuronal cyclooxygenase-2-mediated prostaglandin E2 production |
| - | in-vitro, | GBM, | SK-N-SH |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
| 4468- | VitC, | Se, | Selenium modulates cancer cell response to pharmacologic ascorbate |
| - | in-vivo, | GBM, | U87MG | - | in-vitro, | CRC, | HCT116 |
| 1828- | VitK3, | VitC, | Pankiller effect of prolonged exposure to menadione on glioma cells: potentiation by vitamin C |
| - | in-vivo, | GBM, | NA |
| 961- | Z, | Zinc Downregulates HIF-1α and Inhibits Its Activity in Tumor Cells In Vitro and In Vivo |
| - | in-vitro, | RCC, | RCC4 | - | vitro+vivo, | GBM, | U373MG | - | in-vitro, | Nor, | HUVECs |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:27 Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid